New imaging agent could light up brain tumors

NCT ID NCT03739411

Recruiting now Diagnosis Sponsor: Susan Chang Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study is testing whether a special MRI dye called hyperpolarized pyruvate is safe and can help doctors see gliomas more clearly. About 140 adults with suspected or confirmed glioma will receive the dye and undergo MRI scans. The goal is to check for side effects and see if the dye improves tumor detection compared to standard imaging.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Hyperpolarized Carbon C 13 Pyruvate
What this could lead to: If successful, this imaging technique could help doctors better detect and diagnose gliomas, potentially guiding treatment decisions.
What could go wrong: This is an early-phase pilot study focused on safety and feasibility, not treatment. The imaging agent may not provide clear benefits over standard MRI, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOMA

Contacts and locations

Show contact details

Locations

University of California, San Francisco
RECRUITING

San Francisco, California, 94143, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.